Pacira Pharmaceuticals, Inc.
FDA Regulatory Profile
Summary
- Total Recalls
- 4
- 510(k) Clearances
- 1
- Inspections
- 16
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|
| D-0567-2024 | Class II | Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, | June 12, 2024 |
| D-0546-2024 | Class II | Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg p | May 7, 2024 |
| D-0621-2020 | Class II | EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL v | November 21, 2019 |
| D-168-2013 | Class II | EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vi | December 17, 2012 |
Recent 510(k) Clearances
| K-Number | Device | Date |
|---|
| K211334 | Iovera System | September 10, 2021 |